Research Progress of Prostate Stem Cell Antigen in Bladder Cancer Treatment

¹ Department of Pathology, Baoding First Central Hospital, Baoding 071000, Hebei Province, China; The Key Laboratory of Molecular Pathology and Early Diagnosis of Tumor in Hebei Province, Baoding 071000, Hebei Province, China,

² Department of Pathology, Cancer Hospital of Tianjin Medical University, National Clinical Medical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Treatment, Tianjin Clinical Medical Research Center of Malignant Cancer, Tianjin 300060, China,

³ Department of Pathology, Baoding First Central Hospital, Baoding 071000, Hebei Province, China; The Key Laboratory of Molecular Pathology and Early Diagnosis of Tumor in Hebei Province, Baoding 071000, Hebei Province, China,

⁴ Department of Thoracic Surgery, Baoding First Central Hospital, Baoding 071000, Hebei Province, China,

⁵ Department of Pathology, Cancer Hospital of Tianjin Medical University, National Clinical Medical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Treatment, Tianjin Clinical Medical Research Center of Malignant Cancer, Tianjin 300060, China,

⁶ Department of Pathology, Baoding First Central Hospital, Baoding 071000, Hebei Province, China; The Key Laboratory of Molecular Pathology and Early Diagnosis of Tumor in Hebei Province, Baoding 071000, Hebei Province, China,

PAR 2022 , 6(5), 51–57; https://doi.org/10.26689/par.v6i5.4337

© 2022 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

In order to study the application effect of prostate stem cell antigen in the treatment of bladder cancer, several literatures have been reviewed in this paper, including the predisposition factors of bladder cancer, clinical treatment methods, progress of prostate stem cell antigen, and nanomaterial probe. This paper presents a feasible method of using luminescent nanomaterials (anti-UCNPs) as biological probes.

References

Zhang Z, Zhang W, Mao W, et al., 2022, Research Progress on Biomarkers of Response to Immunotherapy for Advanced Bladder Cancer. Shandong Medicine, 62(02): 93–96.

Che W, Sun Y, Tan Z, et al., 2021, Research Progress on FGFR3 Gene Mutation and Targeted Drug Therapy for Bladder Cancer. Life Science, 33(09): 1133–1142.

Luo L, Luan H, Zheng H, et al., 2022, Study on the Disease Burden of Prostate Cancer, Bladder Cancer and Kidney Cancer Attributable to Smoking in China from 1990 to 2019. Chinese Journal of Evidence-Based Medicine, 22(05): 530–536.

Nie S, 2021, Smoking: A High Risk Factor for Bladder Cancer. Family Medicine. Happy Health, 2021(10): 82.

Yang J, Dong X, Qiao X, et al., 2020, Urine Urothelial Carcinoembryonic Antigen 1 Gene Expression and Significance in Bladder Cancer Patients. Chinese Journal of Practical Diagnosis and Treatment, 34(11): 1099–1102.

Xu H, Li K, Liang Y, et al., 2019, Incidence and Trend Analysis of Bladder Cancer in Guangzhou from 2004 to 2016. China Oncology, 28(12): 913–917.

Song Y, 2019, Association of Single Nucleotide Polymorphism rs762551 with Risk and Prognosis of Bladder Cancer, Shandong University.

Cai Z, 2021, Research on Abnormal Changes in DNA Copy Number as a Molecular Marker for Prognostic Judgment of Bladder Cancer, Molecular Mechanism and Significance of the Interaction Between Viral Mirna and Host in Epstein-Barr Virus-Related Epithelial Malignant Tumors, Peking Union Medical College.

Zhang S, 2021, The Effect of SAPCD2 Gene on the Proliferation and Apoptosis of Bladder Cancer T24 Cells, Kunming Medical University.

Zhang C, 2021, Functional Study of Circular RNA circPGM5 in Regulating Bladder Cancer Cell Progression, Wannan Medical College.

Wang F, Wang D, Zhou Y, 2021, Effects of Transurethral Bipolar Plasma Resection for Bladder Cancer on Intraoperative Blood Loss, Operation Time and Catheter Indwelling Time. Hebei Medicine, 43(24): 3752–3754 + 3758.

Liang Y, Shen M, Chen J, 2021, Clinical Study of Radical Cystectomy for Well-Differentiated T1 Bladder Cancer. Zhejiang Trauma Surgery, 26(06): 1038–1039.

Ma Y, Shan Z, Guo L, et al., 2021, Clinical Effect Analysis of Multi-Technology Fusion Surgery in the Treatment of Non-Muscle Invasive Bladder Cancer. Modern Journal of Genitourinary Oncology, 13(06): 330–335.

Urological Oncology Collaborative Group of China Cancer Hospital, 2022, Chinese Consensus on Multidisciplinary Diagnosis and Treatment of Bladder Cancer and Bladder Preservation Therapy. Chinese Journal of Oncology, 44(03): 209–218.

Wu R, Bai Y, Tang Y, et al., 2021, Research Progress of Molecular Typing to Guide the Treatment of Muscle-Invasive Bladder Cancer. Journal of Clinical Urology, 36(08): 668–671.

Shang G, Liu J, Yu H, et al., 2020, Expression and Detection of Prostate Stem Cell Antigen and Its Single-Chain Antibody-Alkaline Phosphatase Fusion Protein. Journal of Anhui Medical University, 55(12): 1968–1971.

You X, Xiang Z, Yi C, et al., 2020, Research Progress of Chimeric Antigen Receptor-Modified T Cells in the Treatment of Prostate Cancer. Tianjin Medicine, 48(10): 1020–1024.

Xue S, Zhang H, 2021, Research Progress of Nanomaterial-Assisted Diagnosis and Treatment of Bladder Cancer. Journal of Community Medicine, 19(22): 1382–1386.

Tao K, 2021, Application of Targeted Multifunctional Nanomaterials in Bladder Cancer Diagnosis and Treatment, Jilin University.

Wang X, Gu H, 2021, Research Progress of Nanomedicine for Bladder Cancer Perfusion Therapy. Ion Exchange and Adsorption, 37(02): 183–192.

Li D, 2020, Study on the Effect of New Nanomaterial Graphene Quantum Dots on Bladder Cancer T24 Cells In Vitro. Qingdao University.

Xu K, Wang H, 2015, Application of Nanomaterials in Bladder Cancer. Journal of Urology (Electronic Edition), 7(04): 1–3 + 7.

Previous article in this issue

Next article in this issue